The latest price target for Biora Therapeutics (NASDAQ:BIOR) was reported by HC Wainwright & Co. on November 18, 2024. The analyst firm set a price target for $23.00 expecting BIOR to rise to within 12 months (a possible 1374.36% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biora Therapeutics (NASDAQ:BIOR) was provided by HC Wainwright & Co., and Biora Therapeutics maintained their buy rating.

There is no last upgrade for Biora Therapeutics

There is no last downgrade for Biora Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biora Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Biora Therapeutics (BIOR) rating was a maintained with a price target of $15.00 to $23.00. The current price Biora Therapeutics (BIOR) is trading at is $1.56, which is out of the analyst’s predicted range.